Synthetic oral factor Xa inhibitors (such as edoxaban, rivaroxaban and apixaban) belong to the latest generation of anticoagulants and their world-wide use by patients at risk of thrombosis and stroke is increasing rapidly. However, usage of factor Xa inhibitors comes at the expense of a risk of uncontrolled and potentially life-threatening bleeding. 

To stop or prevent – the latter in the case of emergency surgery – these bleedings one needs a reversal agent as an antidote. VarmX has a product in its pipeline called VMX-COO1 that promises safe and effective reversal.

Recent Milestones: Completed FIH studies in 2023 with efficacy read-out. Scaled manufacturing process to commercial level.
Upcoming Milestones: Series C financing, Initiate successive clinical studies pending regulatory interactions Products: Single dose Injectable Factor X bypass factor for reversing the coagulation system in patients treated with DOAC blood thinners
Investors: BGV, EQT, Ysios, Inkef, Lundbeckfund Venture, Sound Bioventures, EIC
Full Company address & contact details: VarmX B.V. Emmy Noetherweg 2 2333 BK Leiden The Netherlands

https://www.varmx.com/